Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211012 | 1.00 | ATM (0.63) | ATMMMP2ANPEPPIN1DPP4 | |
| SCHEMBL29231126 | 1.00 | ATM (0.63) | ATMMMP2ANPEPPIN1DPP4 | |
| SCHEMBL5211015 | 1.00 | ATM (0.63) | ATMMMP2ANPEPPIN1DPP4 | |
| SCHEMBL5211019 | 1.00 | ATM (0.63) | ATMMMP2ANPEPPIN1DPP4 | |
| SCHEMBL16105109 | 0.83 | ATM (0.42) | ATMPIN1DPP4DPP8DPP9 | |
| SCHEMBL22029235 | 0.83 | ATM (0.42) | ATMPIN1DPP4DPP8DPP9 | |
| SCHEMBL5068781 | 0.83 | ATM (0.42) | ATMPIN1DPP4DPP8DPP9 | |
| SCHEMBL6917334 | 0.83 | ATM (0.42) | ATMPIN1DPP4DPP8DPP9 | |
| SCHEMBL3183947 | 0.83 | ATM (0.42) | ATMPIN1DPP4DPP8DPP9 | |
| SCHEMBL3614287 | 0.83 | ATM (0.42) | ATMPIN1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-01-03 | — | — | US | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-9303034-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ATM 3769/4885MMP2 1041/4885ANPEP 1908/4885 |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ATM 3769/4885MMP2 1041/4885ANPEP 1908/4885 |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | ATM 3769/4885MMP2 1041/4885ANPEP 1908/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | ATM 3769/4885MMP2 1041/4885ANPEP 1908/4885 |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ATM 3769/4885MMP2 1041/4885ANPEP 1908/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ATM 3769/4885MMP2 1041/4885ANPEP 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.